Australia markets closed

Seres Therapeutics, Inc. (MCRB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
7.15+0.09 (+1.27%)
At close: 01:00PM EST
7.59 +0.44 (+6.15%)
After hours: 03:36PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 879.62M
Enterprise value 722.65M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)48.76
Price/book (mrq)13.01
Enterprise value/revenue 50.03
Enterprise value/EBITDA -3.29

Trading information

Stock price history

Beta (5Y monthly) 2.79
52-week change 3-18.93%
S&P500 52-week change 3-13.51%
52-week high 311.69
52-week low 32.50
50-day moving average 36.91
200-day moving average 35.67

Share statistics

Avg vol (3-month) 31M
Avg vol (10-day) 3562.82k
Shares outstanding 5124.59M
Implied shares outstanding 6N/A
Float 892.98M
% held by insiders 16.67%
% held by institutions 185.74%
Shares short (30 Oct 2022) 44.77M
Short ratio (30 Oct 2022) 45.45
Short % of float (30 Oct 2022) 45.39%
Short % of shares outstanding (30 Oct 2022) 43.83%
Shares short (prior month 29 Sept 2022) 44.93M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022

Profitability

Profit margin 0.00%
Operating margin (ttm)-1,701.92%

Management effectiveness

Return on assets (ttm)-40.18%
Return on equity (ttm)-190.17%

Income statement

Revenue (ttm)13.37M
Revenue per share (ttm)0.13
Quarterly revenue growth (yoy)-97.30%
Gross profit (ttm)3.04M
EBITDA -221.06M
Net income avi to common (ttm)-231.36M
Diluted EPS (ttm)-0.94
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)233M
Total cash per share (mrq)1.87
Total debt (mrq)76.04M
Total debt/equity (mrq)112.51
Current ratio (mrq)3.03
Book value per share (mrq)0.54

Cash flow statement

Operating cash flow (ttm)-227.79M
Levered free cash flow (ttm)-129.89M